RE:adcom transcript of vote confirms to me...
ps i forgot to add two points of relevance:
a) page 84 of the transscript is critical, read it and ponder what it means, the FDA can't in any Adcom briefing state it has decided already to approve or not, but instead uses appropriate language like "it appears...could benefit..." which means to me it needs countervailing evidence to not approve and this Adcom didn't provide it
b) my real time comparable BMRN got a "will delay decision" from FDA today (precursor to the kiss of death) as i posted before FDA at Adcom stated that BMRN DMD drug "kills".. bad safety = non-approvable, barely efficicasious and safe is entirely approvable for 2nd line, with no SoC and surgery options still available